AstraZeneca To Buy Amolyt Pharma For Up To $1.05 Bln To Expand Late-stage Rare Disease Pipeline

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Thursday that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on rare endocrine diseases. https://www.nasdaq.com/articles/astrazeneca-to-buy-amolyt-pharma-for-up-to-$1.05-bln-to-expand-late-stage-rare-disease